RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer

Wang,Yuan; Qiu,Haifeng; Hu,Weixu; Li,Shaoru; Yu,Jinjin

doi:10.3892/or.2014.2990

RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer

Authors:
- Yuan Wang
- Haifeng Qiu
- Weixu Hu
- Shaoru Li
- Jinjin Yu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Affiliated Hospital of Jiangnan University and the Fourth People's Hospital of Wuxi, Wuxi, Jiangsu 214062, P.R. China, Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital of the China Welfare Institute Affiliated to Shanghai Jiaotong University, Shanghai 200030, P.R. China, Department of Radiation Oncology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/or.2014.2990
Pages: 1389-1395

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RPRD1B, the regulation of nuclear pre-mRNA domain containing 1B gene, functions as a cell cycle manipulator and has been found overexpressed in a small panel of endometrial cancer types. In the present study, we investigated the roles of RPRD1B in endometrial cancer using various in vitro and in vivo experiments. According to our results, RPRD1B mRNA was significantly upregulated in endometrial cancer tissues (P=0.0012). RPRD1B overexpression was correlated with tumor stage (P=0.0004), histology type (P=0.0146) and depth of myometrial invasion (P=0.024). In vitro, RPRD1B promoted cellular proliferation (P=0.032 for MTT assay and P=0.018 for colony formation assay), and accelerated the cell cycle (P=0.007) by upregulating cyclin D1, CDK4 and CDK6, while knockdown of RPRD1B suppressed cellular proliferation (P=0.02 for MTT assay and P=0.031 for colony formation assay), and led to G1 phase arrest (P=0.025) through downregulating cyclin D1, CDK4 and CDK6. Consistently, in the nude mice model, RPRD1B overexpression significantly accelerated the tumor xenograft growth (P=0.0012), accompanied by elevated Ki-67 and cyclin D1. In addition, we demonstrated that downregulating RPRD1B could sensitize Ishikawa cells to Raloxifene (P=0.01). In summary, we demonstrated that RPRD1B was frequently overexpressed in human endometrial cancer. Both in vitro and in vivo, over-abundant RPRD1B could promote tumor growth and accelerate cellular cell cycle. In addition, knockdown of RPRD1B also increased cell sensitivity to Raloxifene, making RPRD1B a potent therapeutic target for endometrial cancer, particularly in patients with resistance to the selective ER modulators.

View Figures

View References

1	Wei KR, Chen WQ, Zhang SW, Zheng RS, Wang YN and Liang ZH: Epidemiology of uterine corpus cancer in some cancer registering areas of China from 2003–2007. Zhonghua Fu Chan Ke Za Zhi. 47:445–451. 2013.(In Chinese).
2	Jamison PM, Noone AM, Ries LA, Lee NC and Edwards BK: Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev. 22:233–241. 2013. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Dos Santos Silva I, Moller H and Weiderpass E: Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 14:1132–1142. 2005. View Article : Google Scholar : PubMed/NCBI
4	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
5	Hecht JL and Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 24:4783–4791. 2006. View Article : Google Scholar : PubMed/NCBI
6	Dedes KJ, Wetterskog D, Ashworth A, Kaye SB and Reis-Filho JS: Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 8:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
8	Boruta DM II, Gehrig PA, Fader AN and Olawaiye AB: Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 115:142–153. 2009. View Article : Google Scholar : PubMed/NCBI
9	Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet. 366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
10	Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR and Ghaem-Maghami S: Endometrial cancer. BMJ. 343:d39542011. View Article : Google Scholar : PubMed/NCBI
11	Del Carmen MG, Boruta DM II and Schorge JO: Recurrent endometrial cancer. Clin Obstet Gynecol. 54:266–277. 2011.
12	Thanapprapasr D and Thanapprapasr K: Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev. 14:3419–3423. 2013. View Article : Google Scholar : PubMed/NCBI
13	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lu D, Wu Y, Wang Y, et al: CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell. 21:92–104. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ni Z, Olsen JB, Guo X, et al: Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. Transcription. 2:237–242. 2011. View Article : Google Scholar : PubMed/NCBI
16	Creasman W: Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009. View Article : Google Scholar : PubMed/NCBI
17	Kim JK and Diehl JA: Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 220:292–296. 2009. View Article : Google Scholar : PubMed/NCBI
18	Massague J: G1 cell-cycle control and cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
19	Mitselou A, Ioachim E, Zagorianakou N, Kitsiou E, Vougiouklakis T and Agnantis NJ: Expression of the cell-cycle regulatory proteins (cyclins D1 and E) in endometrial carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor gene products (p53, pRb), and clinicopathological parameters. Eur J Gynaecol Oncol. 25:719–724. 2004.
20	Semczuk A and Jakowicki JA: Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett. 203:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
21	Horree N, van Diest PJ, Sie-Go DM and Heintz AP: The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol. 38:1232–1238. 2007. View Article : Google Scholar : PubMed/NCBI
22	Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 1602:73–87. 2002.PubMed/NCBI
23	Martin A, Odajima J, Hunt SL, et al: Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27^Kip1 and p21^Cip1. Cancer Cell. 7:591–598. 2005. View Article : Google Scholar : PubMed/NCBI
24	Lundberg AS and Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 18:753–761. 1998.
25	Rane SG, Dubus P, Mettus RV, et al: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat Genet. 22:44–52. 1999.PubMed/NCBI
26	Rosu-Myles M, Taylor BJ and Wolff L: Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol. 35:394–406. 2007. View Article : Google Scholar : PubMed/NCBI
27	Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:753–758. 1997. View Article : Google Scholar : PubMed/NCBI
28	Maximov PY, Lee TM and Jordan VC: The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 8:135–155. 2013. View Article : Google Scholar : PubMed/NCBI